DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Ridgeback Biotherapeutics - 1 Molnupiravir - 1 Merck - 1 Michael Erman - 1 Bill Berkrot - 1
Top related locs:
U.S United States
Top related orgs:
Merck & Co - 1 Merck & Co Inc - 1 Merck - 1 Co Inc - 1 REUTERS - 1 U.S - 1 Co's - 1 Administration - 1

Search resuls for: "Ridgeback Biotherapeutics"


4 mentions found


☆ US plans shift of Merck COVID treatment to commercial market
  + stars: | 2023-10-04 | by ( Michael Erman | ) www.reuters.com   time to read: +3 min
A COVID-19 treatment pill, called molnupiravir developed by Merck & Co and Ridgeback Biotherapeutics LP is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS/File photo Acquire Licensing RightsOct 4 (Reuters) - The U.S. government will stop distributing free doses of Merck & Co's (MRK.N) COVID-19 antiviral treatment molnupiravir by the middle of next month and expects it to be sold on the commercial market instead. Molnupiravir was initially hailed as a potential breakthrough when few treatment options were available but was soon eclipsed by Pfizer's (PFE.N) rival treatment Paxlovid, which had more impressive data. Merck said the study was limited and that it is confident in the clinical profile of the drug. Merck said it would have a patient assistance program for people who cannot afford the drug.
Persons: Ridgeback Biotherapeutics, Molnupiravir, Merck, Michael Erman, Bill Berkrot Organizations: Merck & Co, Merck & Co Inc, Reuters, Merck, Co Inc, REUTERS, U.S, Co's, Administration, Strategic Preparedness, U.S . Department of Health, Human Services, U.S . Food, Drug Administration, Pfizer's, Thomson Locations: U.S, United States
☆ EU regulator recommends against approval for Merck's COVID pill for adults
  + stars: | 2023-02-24 | by ( ) www.reuters.com   time to read: +1 min
Companies Merck & Co Inc FollowFeb 24 (Reuters) - The European Union's drug regulator said on Friday its Committee for Medicinal Products for Human Use has advised against market authorisation of the COVID-19 pill from Merck & Co Inc (MRK.N) for treatment in adults. Merck and its partner Ridgeback Biotherapeutics said they will appeal the decision and request a re-examination of the committee's opinion. "The CHMP's recommendation does not reflect the compelling data" from one of the company's late-stage trial and real-world studies, Dean Li, head of Merck's research division, said. In December, a large study had shown that the drug sped up recovery but did not reduce hospitalisation or death rate in higher-risk vaccinated adults. The regulator's recommendation against Merck's COVID-19 pill comes days after the company said Lagevrio was not effective at cutting the risk of coronavirus infections in people living with someone infected with the virus.
☆ Merck third-quarter earnings climb, lifts full-year outlook
  + stars: | 2022-10-27 | by ( Michael Erman | ) www.reuters.com   time to read: +1 min
Oct 27 (Reuters) - Merck & Co (MRK.N) on Thursday posted better-than-expected third-quarter sales and earnings on a strong performance by its blockbuster cancer immunotherapy drug Keytruda and human papillomavirus vaccine Gardasil. The drugmaker also raised its full-year sales and earnings forecasts despite headwinds created by the weak euro and pound. Third-quarter sales climbed 14% to $15.0 billion, ahead of a Refinitiv consensus estimate of $14.1 billion. Merck now expects full-year sales between $58.5 billion and $59 billion, up from its previous range of $57.5 billion to $58.5 billion. It exects full-year profit in the range of $7.32 to $7.37 per share.
☆ Merck agrees to allow Sinopharm to sell molnupiravir COVID drug in China
  + stars: | 2022-09-28 | by ( ) www.reuters.com   time to read: +1 min
NEW YORK, Sept 28 (Reuters) - Drugmaker Merck & Co (MRK.N) said on Wednesday that it agreed to allow China's Sinopharm (1099.HK) to distribute and import its COVID-19 antiviral molnupiravir in China if the drug is approved for use there. The drugmaker said in a statement that it reached a cooperation framework agreement with Sinopharm that grants the Chinese company distribution and exclusive import rights of the medicine in the China mainland market. Merck also said it will allow China National Biotec Group, an affiliate of Sinopharm, to make the drug in China and has agreed to transfer technology to help with that production. Molnupiravir is sold under the brand name Lagevrio in the U.S. Merck developed the pill - and shares the profits equally - with partner Ridgeback Biotherapeutics. Register now for FREE unlimited access to Reuters.com RegisterReporting by Michael Erman; editing by Jonathan OatisOur Standards: The Thomson Reuters Trust Principles.
0 next >>
Total: 4